International study supports dupilumab for treatment of moderate-to-severe asthma in children
WHO: Omicron could spread faster but it’s still not certain
8 December 2021Removing ovaries, fallopian tubes during non-cancerous hysterectomy safer for post-menopausal patients: study
9 December 2021International study supports dupilumab for treatment of moderate-to-severe asthma in children
A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11.
